Material and Methods: Retrospective case series. A single session of subthreshold 577nm yellow wavelength MPL treatment was performed in 23 eyes of 18 patients with center involved DME. In all but one patient, previous intravitreal anti vascular endothelial growth factor (IV anti-VEGF) and/or IV steroid treatment and/or conventional laser treatment had been performed. In patients with > 300? central macular thickness (CMT) at the fi rst control visit, IV anti-VEGF treatment was performed if deemed necessary. Treatment effi cacy was evaluated by comparing CMT and best corrected visual acuity (BCVA) before treatment and at fi rst and second control visits and assessing the ratio of patients with CMT ? 300? or whose CMT decreased at least 10% at first control visit compared to pre-treatment.

Results: CMT was not found different when compared between pre and post-treatment at fi rst control visit. A signifi cant decrease in CMT was assessed at second visit. CMT decreased at least 10% or was 300? or less at first visit post-treatment. BCVA was not found different at first and second visits compared to pre-treatment. Conclusion: Yellow subthreshold MPL treatment might be effective in DME solely or additional to anti-VEGF agents. Its role in treatment should be better assessed by prospective controlled studies. Keywords : Diabetic macular edema, micropulse laser, subthreshold laser, yellow laser